CUA Educational Content

The evolving landscape of PSMA-targeted radioligand therapies in mCRPC

Speaker: Oliver Sartor

Objectives:

  • Summarize recent advances in mCRPC, focusing on treatment decision making and patient centric approach to treatment.
  • Discuss the place of 177LuPSMA-617 in mCRPC in the context of the wider treatment landscape.
  • Share best practices regarding the implementation of PSMA-targeted RLT in a multi-disciplinary clinical practice.

VIDEO FROM NOVEMBER 27:



VIDEO FROM NOVEMBER 30:

Start Quiz for Credits

ACCREDITATION

This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.

This program has received financial support from Novartis in the form of an educational grant.

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy